Negativity ‘Hurt Us’: Bharat Biotech Chairman Dr Krishna Ella On Delay In WHO Nod To Covaxin

New Delhi: Bharat Biotech’s founder and chairperson Dr Krishna Ella on Wednesday opened up about how unfavourable publicity led to delay in Covaxin getting Emergency Use Itemizing (EUL) by the World Well being Group (WHO).

Scientist Krishna Ella can be Managing Director of the Hyderabad-based biotechnology firm.

Talking on the Instances Now Summit 2021, Dr Krishna Ella elaborated concerning the hurdles confronted in Covaxin’s WHO approval, saying: “We have 5 vaccines WHO pre-qualified so we knew it very well, we know how to do it. But the problem is many media people who are negative, they even wrote to the scientific journals to look into some death in Bhopal. It happened because of suicide but it was blamed on vaccine”.

“The way anti-things happen, that has hurt us more. I want people to realise instead of criticising just ask us, we will tell the truth. But making own opinion that hurt us very badly – that got delayed, some of the process. Whether our publications got delayed or our WHO pre-qualification was delayed because they have to investigate a lot of things… We are very transparent, we are truthful and we won the game,” he added, stating how the negativity damage numerous processes for Covaxin.

ALSO READ | ‘Har Ghar Dastak’ Marketing campaign: Mandaviya To Maintain Assembly With State Well being Ministers On COVID Vax Drive

When requested concerning the motive behind the unfavourable publicity, the Bharat Biotech founder responded: “When Prime Minister took the vaccine, immediately they said it’s a BJP vaccine, it’s a Modi vaccine. All sorts of synonyms. We are scientists, we don’t understand the politics”.

After a protracted wait, WHO granted emergency use itemizing (EUL) to Covaxin, India’s indigenous vaccine towards Coronavirus, on November 3.

The WHO acknowledged that its Technical Advisory Group decided that Bharat Biotech’s vaccine meets WHO requirements for defense towards COVID-19. 

“The Technical Advisory Group, convened by WHO and made up of regulatory consultants from all over the world, has decided that the Covaxin vaccine meets WHO requirements for defense towards COVID-19, that the advantage of the vaccine far outweighs dangers and the vaccine can be utilized,” the WHO tweeted. 

Covaxin was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) and the vaccine was recommended to be administered in two doses, with a dose interval of four weeks, in all age groups 18 and above.

Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )

Calculate The Age Via Age Calculator

Supply hyperlink

Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *